menu
    • menu
    [{"orgOrder":0,"company":"Organogenesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Cryopreserved Amniotic Suspension Allograft","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Organogenesis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-arterial Injection","sponsorNew":"Organogenesis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Organogenesis \/ Inapplicable"},{"orgOrder":0,"company":"Organogenesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cryopreserved Amniotic Suspension Allograft","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Organogenesis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-arterial Injection","sponsorNew":"Organogenesis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Organogenesis \/ Inapplicable"},{"orgOrder":0,"company":"Organogenesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cryopreserved Amniotic Suspension Allograft","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Organogenesis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-arterial Injection","sponsorNew":"Organogenesis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Organogenesis \/ Inapplicable"},{"orgOrder":0,"company":"Organogenesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Cryopreserved Amniotic Suspension Allograft","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Organogenesis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-arterial Injection","sponsorNew":"Organogenesis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Organogenesis \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Organogenesis

    Menu

    Organogenesis

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Organogenesis

                            U.S.A arrow
                            RDD 2025
                            Not Confirmed

                            Organogenesis

                            U.S.A arrow
                            RDD 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cryopreserved Amniotic Suspension Allograft

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Organogenesis Reports Positive Phase 3 ReNu Data for Knee Osteoarthritis Treatment

                            Details : ReNu, a cryopreserved amniotic suspension allograft, for the management of symptoms associated with knee osteoarthritis achieved its primary endpoint upon the analysis of positive top line data.

                            Product Name : ReNu

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            November 11, 2024

                            Lead Product(s) : Cryopreserved Amniotic Suspension Allograft

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Organogenesis

                            U.S.A arrow
                            RDD 2025
                            Not Confirmed

                            Organogenesis

                            U.S.A arrow
                            RDD 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cryopreserved Amniotic Suspension Allograft

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Organogenesis Achieves Primary Endpoint In Phase 3 Trial Of ReNu® For Knee Osteoarthritis

                            Details : ReNu, a cryopreserved amniotic suspension allograft, for the management of symptoms associated with knee osteoarthritis achieved its primary endpoint upon the analysis of positive top line data.

                            Product Name : ReNu

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            February 05, 2024

                            Lead Product(s) : Cryopreserved Amniotic Suspension Allograft

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Organogenesis

                            U.S.A arrow
                            RDD 2025
                            Not Confirmed

                            Organogenesis

                            U.S.A arrow
                            RDD 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cryopreserved Amniotic Suspension Allograft

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Organogenesis Reports Positive Interim Analysis of Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis

                            Details : ReNu (cryopreserved amniotic suspension allograft) has shown promising anti-inflammatory and chondroregenerative potential. It is being studied for the treatment of moderate to severe symptomatic knee osteoarthritis (OA).

                            Product Name : ReNu

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            January 03, 2023

                            Lead Product(s) : Cryopreserved Amniotic Suspension Allograft

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Organogenesis

                            U.S.A arrow
                            RDD 2025
                            Not Confirmed

                            Organogenesis

                            U.S.A arrow
                            RDD 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cryopreserved Amniotic Suspension Allograft

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Organogenesis Enrolls First Patient in Pivotal Phase 3 Clinical Trial of RMAT-Designated ReNu® for Knee Osteo...

                            Details : The Phase 3 study is a prospective, double-blind, multicenter, placebo-controlled, parallel group, randomized control trial (RCT) of ReNu in 474 subjects with moderate to severe symptomatic knee osteoarthritis.

                            Product Name : ReNu

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            January 14, 2021

                            Lead Product(s) : Cryopreserved Amniotic Suspension Allograft

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth